A federal judge has allowed parts of a shareholder lawsuit against Novo Nordisk to proceed, alleging the company misled investors regarding its experimental weight-loss drug, CagriSema. The core dispute involves claims that Novo presented misleading information about the clinical trial design and tolerability of CagriSema...
Novo Nordisk shares dropped approximately 6% on Tuesday following the release of its second-quarter financial results, which showed a miss in oral Wegovy sales despite an improved full-year outlook. The Danish pharmaceutical giant reported adjusted Q2 sales of 78.49 billion Danish kroner ($12.1 billion), representing...
Novo Nordisk (NVO) shares dropped sharply on July 31 after its experimental heart drug, Ziltivekimab, failed to meet the primary endpoint of the large-scale ZEUS late-stage trial. The Danish pharmaceutical giant had been counting on this cardiovascular asset to serve as a second growth engine...
On July 29, 2026, the Federal Trade Commission (FTC), joined by Utah and Los Angeles County, sued Hims & Hers Health, Inc. in Northern District of California. The lawsuit alleges deceptive practices regarding data sharing with advertising platforms like Meta and Snap, false claims about...
A U.S. federal judge in Trenton, New Jersey, ruled on Tuesday that Novo Nordisk must face a shareholder lawsuit alleging fraud regarding its CagriSema weight loss trial. The court found sufficient evidence that Martin Holst Lange, the company's former executive vice president of development and...
Novo Nordisk (NVO) faces a significant market reset in 2026, characterized by declining U.S. pricing, intense competition from Eli Lilly, and a pipeline setback with CagriSema missing its primary endpoint. Consequently, the company has guided to adjusted sales declines of 4% to 12% for the...
Novo Nordisk (NVO) is identified as a BUY opportunity because its business fundamentals are recovering faster than its current stock price, primarily driven by the historic U.S. launch of oral Wegovy. The article highlights that over 3 million prescriptions for oral Wegovy were filled in...
Novo Nordisk (NVO) shares have declined significantly over the past three years, dropping 36.4%, with a more recent 0.9% return that lags behind industry peers. Despite these price movements and negative sentiment swings, the company currently trades at a P/E multiple of 11.1x, which is...
Novo Nordisk (NVO) shares finished the week with a modest rally, closing Friday at DKK 326.90 despite a 1.54% daily drop, resulting in a 2.8% weekly gain that lagged the OMX Copenhagen 25 benchmark by 2.6 percentage points. Trading volume remained thin, hitting 2.58 million...
Novo Nordisk (NVO) stock has declined over 30% since mid-2024, continuing a downtrend that analysts view as a potential generational buying opportunity ahead of the company's upcoming Q2 earnings report. Investors are shifting their focus from immediate quarterly beats to management's confidence in executing long-term...
Novo Nordisk shares have rallied approximately 27% since the author's last coverage, driven primarily by accelerating commercial momentum for its oral Wegovy formulation and expanding investor confidence. The article highlights that Novo Nordisk has captured roughly 89% of new U.S. prescriptions for oral Wegovy compared...
Novo Nordisk (NYSE:NVO) has secured European Commission marketing authorization for oral Wegovy and a higher-dose injectable formulation across the EU, covering 27 countries plus Norway, Iceland, and Liechtenstein. These approvals expand access to GLP-1 based obesity treatments by introducing an oral convenience option alongside an...
Novo Nordisk announced significant price reductions for its Ozempic and Wegovy drugs starting in January 2027, with costs dropping to $675 per dose. Concurrently, the company is expanding access through partnerships, including a deal with Costco to offer members a four-week supply for $499 and...
Novo Nordisk has filed a lawsuit in the U.S. seeking an immediate preliminary injunction to block advertising campaigns for Eli Lilly's weight-loss drugs, Zepbound and Mounjaro. The Danish company alleges that Lilly's advertisements rely on outdated studies and misleadingly compare high doses of Lilly's products...
Novo Nordisk A/S (NYSE: NVO) has filed a lawsuit against Eli Lilly and Company (NYSE: LLY) in New Jersey federal court. The legal action centers on allegations that Lilly's advertising campaigns for its GLP-1 weight-loss drugs falsely claim superior efficacy compared to Novo's products. The...
Novo Nordisk has entered into an outsourcing agreement with Shantha Biologics to handle cartridge fill-finish manufacturing services in India. This strategic partnership expands Novo Nordisk's production footprint into a key pharmaceutical hub, specifically targeting the supply of cartridge-based products used for its GLP-1 and broader...
